Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (61-70 of 187) with videos related to

Pageof 19
Sort By:
Cancer Research|January 11, 2007
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulinHua Zhang, Alissa M Pelzer, David T Kiang, et al.
Breast Cancer Research and Treatment|August 19, 2011
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptorXianke Zeng, Hua Zhang, Annabell Oh, et al.
Hormones & Cancer|September 20, 2018
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer CellsYuzhe Yang, Jie Ying Chan, Nuri A Temiz, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteinsKathryn H Schmitz, Rehana L Ahmed, Peter J Hannan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivoXianke Zeng, Deepali Sachdev, Hua Zhang, et al.
Medical Care|July 13, 2023
Was Unstable Medicaid Coverage Among Older Medicare Beneficiaries Associated With Worse Clinical Outcomes? Evidence From the Delivery of Breast Cancer CareXuanzi Qin, Peter Huckfeldt, Jean Abraham, et al.
Journal of the National Cancer Institute|March 25, 2022
Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast CancerXuanzi Qin, Peter Huckfeldt, Jean Abraham, et al.
Research in Social & Administrative Pharmacy : RSAP|December 28, 2020
Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choiceXuanzi Qin, Peter Huckfeldt, Jean Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2016
Neoadjuvant as Future for Drug Development in Breast Cancer--ResponseAngela DeMichele, Douglas Yee, Melissa Paoloni, et al.
The Journal of Biological Chemistry|November 15, 2003
A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cellsDeepali Sachdev, Julie S Hartell, Adrian V Lee, et al.
Pageof 19

Showing results (61-70 of 187) with videos related to

Sort By:
Pageof 19
Cancer Research|January 11, 2007
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulinHua Zhang, Alissa M Pelzer, David T Kiang, et al.
Breast Cancer Research and Treatment|August 19, 2011
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptorXianke Zeng, Hua Zhang, Annabell Oh, et al.
Hormones & Cancer|September 20, 2018
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer CellsYuzhe Yang, Jie Ying Chan, Nuri A Temiz, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 21, 2005
Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteinsKathryn H Schmitz, Rehana L Ahmed, Peter J Hannan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivoXianke Zeng, Deepali Sachdev, Hua Zhang, et al.
Medical Care|July 13, 2023
Was Unstable Medicaid Coverage Among Older Medicare Beneficiaries Associated With Worse Clinical Outcomes? Evidence From the Delivery of Breast Cancer CareXuanzi Qin, Peter Huckfeldt, Jean Abraham, et al.
Journal of the National Cancer Institute|March 25, 2022
Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast CancerXuanzi Qin, Peter Huckfeldt, Jean Abraham, et al.
Research in Social & Administrative Pharmacy : RSAP|December 28, 2020
Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choiceXuanzi Qin, Peter Huckfeldt, Jean Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2016
Neoadjuvant as Future for Drug Development in Breast Cancer--ResponseAngela DeMichele, Douglas Yee, Melissa Paoloni, et al.
The Journal of Biological Chemistry|November 15, 2003
A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cellsDeepali Sachdev, Julie S Hartell, Adrian V Lee, et al.
Pageof 19